Globus Medical, Inc. $GMED Shares Acquired by Kingdon Capital Management L.L.C.

Kingdon Capital Management L.L.C. lifted its holdings in Globus Medical, Inc. (NYSE:GMED) by 51.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 257,650 shares of the medical device company’s stock after buying an additional 87,650 shares during the quarter. Globus Medical makes up 1.8% of Kingdon Capital Management L.L.C.’s portfolio, making the stock its 14th biggest position. Kingdon Capital Management L.L.C. owned approximately 0.19% of Globus Medical worth $14,756,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. ANTIPODES PARTNERS Ltd grew its stake in shares of Globus Medical by 49,020.3% in the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock worth $51,034,000 after purchasing an additional 889,229 shares in the last quarter. Paradice Investment Management LLC grew its position in Globus Medical by 20.9% in the 3rd quarter. Paradice Investment Management LLC now owns 663,038 shares of the medical device company’s stock valued at $37,972,000 after buying an additional 114,433 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of Globus Medical by 17.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after purchasing an additional 414,134 shares during the last quarter. Foresight Group Ltd Liability Partnership raised its holdings in shares of Globus Medical by 160.7% in the 3rd quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock worth $24,142,000 after purchasing an additional 259,870 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Globus Medical by 189.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 476,531 shares of the medical device company’s stock valued at $27,953,000 after acquiring an additional 312,149 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Globus Medical

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leslie V. Norwalk sold 2,000 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the transaction, the director owned 10,419 shares in the company, valued at approximately $1,053,360.90. The trade was a 16.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 35,594 shares of company stock valued at $3,332,253 over the last ninety days. 18.54% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GMED has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their price target on Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Canaccord Genuity Group increased their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a report on Friday, January 9th. Morgan Stanley lifted their price target on shares of Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th. Finally, Piper Sandler restated an “overweight” rating and set a $115.00 price target (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical Trading Up 0.4%

Globus Medical stock opened at $84.81 on Monday. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The business has a 50-day moving average of $90.71 and a 200-day moving average of $78.49. The firm has a market capitalization of $11.47 billion, a P/E ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. During the same quarter in the prior year, the business posted $0.84 EPS. The business’s revenue was up 25.7% compared to the same quarter last year. Research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.